Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13980103 | 1.00 | PDE3B (0.40) | PDE3BPDE3AKDM4EUSP2HPGD | |
| SCHEMBL18858530 | 0.90 | PDE3B (0.44) | PDE3BPDE3AKDM4EUSP2HPGD | |
| SCHEMBL27355631 | 0.83 | — | — | |
| SCHEMBL24202601 | 0.82 | PDE3B (0.30) | PDE3BPDE3A | |
| SCHEMBL27289776 | 0.82 | PDE3B (0.30) | PDE3BPDE3A | |
| SCHEMBL34472956 | 0.82 | PDE3B (0.39) | PDE3BPDE3A | |
| SCHEMBL1131513 | 0.82 | PDE3B (0.39) | PDE3BPDE3A | |
| Ammonia Solution, Strong SCHEMBL28980458 | 0.79 | PDE3B (0.38) | PDE3BPDE3A | |
| SCHEMBL30110738 | 0.76 | PDE3B (0.40) | PDE3BPDE3AKDM4EUSP2HPGD | |
| SCHEMBL1532455 | 0.76 | PDE3B (0.40) | PDE3BPDE3AKDM4EUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | BIOMEA FUSION, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | FLT3, MCL1, JAK2 | PDE3B 2138/4885PDE3A 2063/4885KDM4E 2031/4885 |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | PDE3B 2642/4885PDE3A 2513/4885KDM4E 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.